Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login
or review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Lecture contents
- Allergy and asthma
- Action of omalizumab
- Clinical trial for omalizumab
- Results of clinical trial
- Secondary outcomes
- Omalizumab licence
- Practical considerations
- Expanded dose table
- What do guidelines say about omalizumab?
- Severe asthma
- Current situation
- SMC decision
- NICE final appraisal determination (1)
- RBH difficult asthma protocol
- NICE final appraisal determination (2)
- Monitoring
- Evidence from Joint task force
- Summary of recommendations
- Summary of timing of adverse reactions
- Monitoring after injections
- NICE vs. SMC
- Median daily OCS use
- Median AQLQ total scores
- Median FEV1
- Current UK practice
- A retrospective analysis of omalizumab treatment
- Objectives
- Eligibility
- Patient demographics
- OCS daily dose
- Percentage stopping or reducing OCS use
- Asthma exacerbations pre and post OMB
- Quality of life pre and post OMB
- NHS resource use - hospitalisations
- NHS resource use - no. days hospitalised
- Lung function pre and post OMB initiation
- How long to treat?
- Research evidence
- FEV1 after omalizumab withdrawal
- Asthma after stopping omalizumab
- Asthma medication changed after omalizumab
- Conclusions
Topics Covered
- Anti-IgE therapy for asthma
- Allergy can be associated with severe asthma
- Omalizumab, a monoclonal anti-IgE, is the first targeted biological therapy for severe asthma with good clinical efficacy
- Patient selection, drug administration and length of treatment are discussed
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Menzies-Gow, A. (2013, January 17). Anti-IgE therapy for asthma [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved January 20, 2021, from https://hstalks.com/bs/2474/.Publication History
Financial Disclosures
- Dr. Andrew Menzies-Gow has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Anti-IgE therapy for asthma
Published on January 17, 2013
24 min